{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-000528","form_type":"8-K","ticker":"GNLX","cik":"0001231457","company_name":"GENELUX Corp","filed_at":"2025-03-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.134895+00:00","generated_at":"2026-05-24T05:32:25.840645+00:00","sec_items":["2.02","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Genelux reports preliminary cash ~$30.9M; positive Olvi-Vec SCLC data and FDA guidance for PRROC","bullets":["Preliminary cash, cash equivalents, and short-term investments as of Dec 31, 2024: ~$30.9M (unaudited).","Phase 1b/2 SCLC data: 71% disease control rate among 7 evaluable patients; 2 partial responses; 79% tumor reduction in one.","FDA Type D meeting for Olvi-Vec in PRROC: FDA indicated clinically meaningful PFS advantage without OS decrement could support traditional approval; pre-BLA meeting recommended.","Anticipates reporting Phase 3 topline (OnPrime/GOG-3076) in H1 2026 and Phase 2 VIRO-25 interim in H2 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-000528","json":"https://secwatch.observer/filing/0001641172-25-000528.json","markdown":"https://secwatch.observer/filing/0001641172-25-000528.md","text":"https://secwatch.observer/filing/0001641172-25-000528.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1231457/000164117225000528/0001641172-25-000528-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1231457/000164117225000528/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T05:32:25.840645+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}